title: The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20.
abstract: Chemotherapy-induced peripheral neuropathy (CIPN) is a common phenomenon, often resulting in serious limitations in daily functioning and compromised quality of life. Currently available toxicity grading systems typically use a combination of clinical and paraclinical parameters and relies on the judgment of clinicians and/or nurses. However, because many of the symptoms of CIPN are subjective in nature, it is only logical that an assessment of CIPN be based, at least in part, on patient self-report data. We report on the development of a patient self-report questionnaire, the CIPN20, intended to supplement the core quality of life questionnaire of the European Organization for Research and Treatment of Cancer (EORTC). Following EORTC guidelines, relevant CIPN-related issues were identified from a literature survey and interviews with health professionals (n=15) and patients (n=112). The resulting 20-item questionnaire was pre-tested in three languages and four countries and is currently being examined in a large, international clinical trial. The EORTC CIPN20 should provide valuable information on CIPN-related symptoms and functional limitations of patients exposed to potentially neurotoxic chemotherapeutic and/or neuroprotective agents.
authors.affiliation: Department of Neurology, VU University Medical Center, P.O. Box 7057, MB Amsterdam 1007, The Netherlands. t.j.postma@vumc.nl
authors.forename: T J
authors.initials: TJ
authors.lastname: Postma
authors.forename: N K
authors.initials: NK
authors.lastname: Aaronson
authors.forename: J J
authors.initials: JJ
authors.lastname: Heimans
authors.forename: M J
authors.initials: MJ
authors.lastname: Muller
authors.forename: J G
authors.initials: JG
authors.lastname: Hildebrand
authors.forename: J Y
authors.initials: JY
authors.lastname: Delattre
authors.forename: K
authors.initials: K
authors.lastname: Hoang-Xuan
authors.forename: M
authors.initials: M
authors.lastname: Lantéri-Minet
authors.forename: R
authors.initials: R
authors.lastname: Grant
authors.forename: R
authors.initials: R
authors.lastname: Huddart
authors.forename: C
authors.initials: C
authors.lastname: Moynihan
authors.forename: J
authors.initials: J
authors.lastname: Maher
authors.forename: R
authors.initials: R
authors.lastname: Lucey
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D011788:Quality of Life; D011795:Surveys and Questionnaires / Q000592:standards*
chemical_list: D000970:Antineoplastic Agents